Company History

1995
JANUARY
Rob Chioini starts Rockwell Medical selling dialysis kits and ancillary items
1996
JANUARY
New 35,000 sq ft site open in Wixom, MI for production of dialysis concentrate
MARCH
First gallon of dialysis concentrate produced
1998
JANUARY
Successful IPO on the NASDAQ stock exchange under symbol RMTI
DECEMBER
Launch Dri-Sate® Dry Acid Mix System and SteriLyte® Liquid Bicarbonate
2001
JULY
Move into new 51,000 sq ft manufacturing facility in Michigan
OCTOBER
Second 51,000 sq ft manufacturing facility added in TX
2002
JANUARY
Rockwell secures worldwide license for proprietary SFP iron delivery technology
GENERAL
Key sales milestone is achieved as Rockwell surpasses $10M in revenue
2005
MARCH
60,000 sq ft faciltiy in South Carolina becomes third manufacturing site
JUNE
E & Y names Rob Chioini Entrepreneur of Year in Michigan GLR
GENERAL
Company reaches $25M in revenue
2006
FEBRUARY
Successful warrant conversion raised $9.3M for SFP safety and pharmacology studies
2007
MID - 2007
Completion of final preclinical study
NOVEMBER
Successful $13M financing for Phase IIb clinical study
2008
GENERAL
Key sales milestone is achieved as Rockwell surpasses $50M in revenue
2009
APRIL
Enrollment for Phase IIb study completed.
SEPTEMBER
Successful $22M financing for SFP clinical development
OCTOBER
Phase IIb clinical study completed
2010
OCTOBER
Received US patent for GMP-grade SFP iron formula
GENERAL
300+ employees and 55 trucks making deliveries across the US
2011
MARCH
Began enrollment for Phase III CRUISE clinical studies & PRIME ESA-sparing study
JULY
Acquired generic Vitamin-D drug to market and sell to dialysis patients
2012
FEBRUARY
Successful $17.5M financing for Phase III clinical trial
APRIL
Enrollment for PRIME clinical study completed
MAY & JULY
Enrollment for CRUISE-1 and CRUISE-2 clinical studies completed
2013
FEBRUARY
Successful completion of PRIME study. Met primary and secondary endpoints
MARCH
Successful $12.9M equity financing for Phase III clinical trial
APRIL
Submitted Calcitriol data for FDA approval
MAY
Successful $40.3M equity financing for Phase III clinical trial
JUNE
Successful $20M debt financing for Phase III clinical trial
JULY & SEPTEMBER
CRUISE-1 and CRUISE-2 Phase III Efficacy clinical trial completed. Met primary and secondary endpoints.
OCTOBER
Phase III safety data published. Met primary and secondary endpoints
GENERAL
DaVita 5-year national supply agreement
GENERAL
FDA approval of Triferic trade name
2014
FEBRUARY
Completed Triferic long term safety study
MARCH
Submitted Triferic New Drug Application to FDA
MAY
FDA accepts Triferic New Drug Application
JUNE
FDA Calcitriol Vitamin D generic approval
OCTOBER
Exclusive long-term agreement with Baxter International for concentrates. $52.5M cash, equity and milestone payments.
NOVEMBER
FDA Advisory Committee recommends Triferic for iron maintenance therapy
NOVEMBER
Successful $58.5M equity financing for new growth opportunities
GENERAL
Company reaches $50M in revenue
2015
JANUARY
Received U.S. Food and Drug Administration approval for Triferic iron maintenance therapy
MARCH
Initiated clinical programs for delivering Triferic TPN Solution, Triferic PD Solution, Triferic IV Solution, and Triferic Orphan Indication
SEPTEMBER
Triferic US Commercial drug launch
2016
FEBRUARY
Exclusive License Agreement with Wanbang Biopharma to Commercialize Triferic in China. $39M cash, milestones and product revenue stream.
FEBRUARY
Files Triferic IND for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia (IRIDA)
AUGUST
Exclusive License Agreement to Commercialize Triferic in Saudi Arabia, Egypt and Middle East targeting 375,000 CKD-HD patients.
2017
MARCH
Announces ESA Sparing, Compositions and Use Patent in China